COS-CAHON-SITC Workshop on Cancer Immunotherapy

April 30, 2016
Taipei, Taiwan

Presented by The Chinese Oncology Society (COS) in collaboration with the Chinese American Hematologist and Oncologist Network (CAHON), National Taiwan University Hospital National Research Program for Biopharmaceuticals, and the Society for Immunotherapy of Cancer (SITC).

This joint session on cancer immunotherapy addressed the mechanisms and efficacy of current and emerging immunotherapy agents and updates on recent research findings in the cancer immunotherapy field.

The session led into the Japan Taiwan Oncology Phase I Trial Conference (JTOPIC) on April 30-May 1. The conference aimed to foster the collaboration of phase I studies between Japan and Taiwan. Key opinion leaders from academia, industry, and regulatory bodies covered a wide range of topics on oncology phase I trials, including the demand, the impact, and even the controversy.

Workshop Topics

Opening Remarks
Ann-Lii Cheng, MD, PhD – National Taiwan University Hospital
Yun Yen, MD, PhD – Taipei Medical University
Wenru Song, Md, PhD – CAHON, SITC
 

Basic Tumor Immunology for Busy Clinicians
Zihai Li, MD, PhD – Medical University of South Carolina CAHON

Immune Checkpoint Combinations in Oncology
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center, SITC

Adoptive T Cell Therapy of Cancers
Chrystal M. Paulos, PhD – Medical University of South Carolina, SITC

Cancer Vaccines: Do we still need them?
Lei Zheng, PhD – Johns Hopkins University School of Medicine, CAHON

Current Immune-oncology Trials in Taiwan
Chia-Chi (Josh) Lin, MD, PhD – National Taiwan University Hospital

Closing Remarks
Ann-Lii Cheng, MD, PhD – National Taiwan University Hospital
Yun Yen, MD, PhD – Taipei Medical University